Cecile Idink - Department of Internal Medicine, ZorgSaam Hospital Terneuzen

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 7 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/next STEP Phase 2 Trial

Mark-David Levin,Sabina Kersting,Julie Dubois,Bronno van der Holt,Caspar da Cunha-Bang,Doreen te Raa,Cecile Idink,Fransien De Boer,Jolanda Droogendijk,Koen de Heer, Leonie van der Burg,Marten R. Nijziel,Lidwine Tick, Henriettte Levenga,Matthijs Silbermann,Inge Ludwig,Aart Beeker,Mar Bellido,Anne-Marie Van Der Kevie-Kersemaekers,Clemens Mellink, Ine Meulendijks, Sjoerd Zoun-van den Dool, Martine Abrahamse-Testroote,Gerben Zwezerijnen,Carsten Utoft Niemann,Arnon P. Kater

Bloodno. Supplement 1 (2024): 1013-1013

Cited0Views0Bibtex

Venetoclax Consolidation after Fixed-Duration Venetoclax Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (HOVON 139/give): Primary Endpoint Analysis of a Multicentre, Open-Label, Randomised, Parallel-Group, Phase 2 Trial

The Lancet Haematology（2022）

Cited19Views0WOSBibtex

COVID-19 Vaccination in Patients with Immune Thrombocytopenia

Chantal Visser,Maurice Swinkels,Erik D. van Werkhoven,F. Nanne Croles, Heike S. Noordzij-Nooteboom,Matthijs Eefting,Suzanne M. Last-Koopmans,Cecile Idink,Peter E. Westerweel,Bart Santbergen,Pieter A. Jobse,Fazil Baboe,Mark-David Levin,Marieke J. H. A. Kruip,A. J. Gerard Jansen

Blood Advances（2021）

Cited39Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn